Payment overview · 2025
General Payments
$513.77
18 reported records · 6 companies
Healthcare provider profile · identity verified
Ousama Ismael, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN BERNARDINO, CA · NPI 1740451079
Verified facts
What the public records show
CMS Open Payments records show Ousama Ismael, MD received $513.77 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $168.02 | 32.7% | 6 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $150.51 | 29.3% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $80.87 | 15.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.41 | 11.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.50 | 6.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.46 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $513.77 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $168.02 | 6 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $150.51 | 5 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $150.51 | 5 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $133.35 | 5 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $102.71 | 4 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $102.25 | 4 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $94.53 | 3 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $80.87 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.41 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.50 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 312 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 267 | 100 |
| Eliquis | Apixaban | 201 | 63 |
| Gabapentin | Gabapentin | 187 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 42 |
| Furosemide | Furosemide | 158 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 40 |
| Potassium Chloride | Potassium Chloride | 112 | 36 |
| Morphine Sulfate Er | Morphine Sulfate | 108 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 46 |
| Lisinopril | Lisinopril | 97 | 46 |
| Famotidine | Famotidine | 90 | 34 |
| Sodium Chloride | 0.9 % Sodium Chloride | 82 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 28 |
| Carvedilol | Carvedilol | 70 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 22 |
| Losartan Potassium | Losartan Potassium | 66 | 30 |
| Metformin Hcl | Metformin Hcl | 66 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 25 |
| Trazodone Hcl | Trazodone Hcl | 53 | 14 |
| Divalproex Sodium | Divalproex Sodium | 52 | 13 |
| Finasteride | Finasteride | 50 | 16 |
| Omeprazole | Omeprazole | 49 | 18 |
| Memantine Hcl | Memantine Hcl | 46 | 12 |
| Midodrine Hcl | Midodrine Hcl | 45 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | 11 |
| Humalog | Insulin Lispro | 44 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 15 |
| Levofloxacin | Levofloxacin | 43 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 16 |
| Silver Sulfadiazine | Silver Sulfadiazine | 42 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 16 |
| Clonidine Hcl | Clonidine Hcl | 40 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 40 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 18 |
| Enoxaparin Sodium | Enoxaparin Sodium | 38 | 19 |
| Morphine Sulfate | Morphine Sulfate | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 19 |
| Ceftriaxone | Ceftriaxone Sodium | 35 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 33 | 12 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 13 |
| Nifedipine Er | Nifedipine | 32 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | 16 |
| Sertraline Hcl | Sertraline Hcl | 31 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 12 |
| Nitroglycerin | Nitroglycerin | 30 | 16 |
| Alprazolam | Alprazolam | 29 | 16 |
| Glipizide | Glipizide | 29 | suppressed |
| Lactulose | Lactulose | 29 | 13 |
| Heparin Sodium | Heparin Sodium,porcine | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 15 |
| Humulin R | Insulin Regular, Human | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | 11 |
| Alendronate Sodium | Alendronate Sodium | 26 | 12 |
| Baclofen | Baclofen | 26 | 11 |
| Ozempic | Semaglutide | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | 12 |
| Simvastatin | Simvastatin | 25 | 11 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Prednisone | Prednisone | 23 | 18 |
| Cephalexin | Cephalexin | 22 | 18 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Cefdinir | Cefdinir | 19 | 15 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | 13 |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Glucagon Emergency Kit | Glucagon | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxacillin Sodium | Oxacillin Sodium | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $513.77 · 18 records | ABBVIE INC. | AVYCAZ, DALVANCE, EMBLAVEO, Kimyrsa, MOUNJARO, Orbactiv, Rezzayo, TEFLARO, Wegovy, YUPELRI, ZEPBOUND, ZERBAXA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error